Treatment of hyperkalemia: something old, something new

Area of Science:

• Nephrology
• Internal Medicine
• Pharmacology

Background:

• Hyperkalemia treatment options have seen limited innovation over the past 50 years.
• Current therapies like sodium polystyrene sulfonate (Kayexalate) have limitations in acute settings and raise safety concerns.
• Existing insulin regimens for hyperkalemia are suboptimal, risking hypoglycemia and insufficient potassium reduction.

Purpose of the Study:

• To review the current landscape of hyperkalemia treatments.
• To evaluate the efficacy and safety of established and novel potassium-binding agents.
• To discuss the potential of new therapies in managing acute and chronic hyperkalemia.

Main Methods:

• Review of existing literature and clinical trial data on hyperkalemia treatments.
• Analysis of the mechanisms of action, efficacy, and safety profiles of sodium polystyrene sulfonate, patiromer, and ZS-9.
• Discussion of the role of insulin, bicarbonate, and hemodialysis in hyperkalemia management.

Main Results:

• Sodium polystyrene sulfonate (Kayexalate) shows efficacy in chronic, but not acute, hyperkalemia treatment, with ongoing gastrointestinal concerns.
• Investigational potassium binders, patiromer and ZS-9, demonstrate effectiveness and good tolerability for chronic use, despite some side effect concerns.
• ZS-9 shows potential for acute hyperkalemia treatment, possibly avoiding or delaying hemodialysis.

Conclusions:

• New potassium binders are expected soon, offering improved chronic management options for hyperkalemia.
• Patiromer and ZS-9 are effective and well-tolerated for chronic hyperkalemia, though potential side effects require monitoring.
• ZS-9 holds promise for acute hyperkalemia, potentially serving as a less invasive alternative to hemodialysis.